- recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-label, Active-Control Study of REGN7508, a Factor XI Monoclonal Antibody, for the Prevention of Venous Thromboembolism in Participants Undergoing an Elective, Unilateral, Total Knee Arthroplasty (ROXI-VTE II)
This study is testing a new medicine, REGN7508, to prevent blood clots after knee replacement surgery. It compares the new medicine with a standard blood clot prevention medicine, Inhixa/Clexane, to see how well it works and if it causes side effects.
Bulgaria · Poland · Hungary - recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty
This study is testing a new medicine called REGN9933 to see if it can prevent blood clots after knee replacement surgery. Blood clots can be serious, so finding good ways to prevent them is important. We're comparing REGN9933 to other common clot-preventing medicines.
Lithuania · Latvia · Poland